Product Name :
Edoxaban (tosylate monohydrate)
Description:
Edoxaban is a potent, selective factor Xa inhibitor, which has good oral bioavailability. Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is being developed by Daiichi Sankyo. It was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism.
CAS:
1229194-11-9
Molecular Weight:
738.27
Formula:
C31H40ClN7O8S2
Chemical Name:
4-methylbenzene-1-sulfonic acid N’-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-{5-methyl-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridine-2-amido}cyclohexyl]ethanediamide hydrate
Smiles :
O.CN(C)C(=O)[C@@H]1C[C@@H](NC(=O)C2=NC3CCN(C)CC=3S2)[C@H](CC1)NC(=O)C(=O)NC1=CC=C(Cl)C=N1.CC1C=CC(=CC=1)S(O)(=O)=O
InChiKey:
PSMMNJNZVZZNOI-SJILXJHISA-N
InChi :
InChI=1S/C24H30ClN7O4S.C7H8O3S.H2O/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10;/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10);1H2/t13-,15-,17+;;/m0.{{Lurasidone} MedChemExpress|{Lurasidone} 5-HT Receptor|{Lurasidone} Purity & Documentation|{Lurasidone} References|{Lurasidone} custom synthesis|{Lurasidone} Autophagy} ./s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥360 days if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Edoxaban is a potent, selective factor Xa inhibitor, which has good oral bioavailability.{{Sotagliflozin} MedChemExpress|{Sotagliflozin} SGLT|{Sotagliflozin} Protocol|{Sotagliflozin} In stock|{Sotagliflozin} manufacturer|{Sotagliflozin} Epigenetics} Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor.PMID:24428212 It is being developed by Daiichi Sankyo. It was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism.|Product information|CAS Number: 1229194-11-9|Molecular Weight: 738.27|Formula: C31H40ClN7O8S2|Chemical Name: 4-methylbenzene-1-sulfonic acid N’-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-{5-methyl-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridine-2-amido}cyclohexyl]ethanediamide hydrate|Smiles: O.CN(C)C(=O)[C@@H]1C[C@@H](NC(=O)C2=NC3CCN(C)CC=3S2)[C@H](CC1)NC(=O)C(=O)NC1=CC=C(Cl)C=N1.CC1C=CC(=CC=1)S(O)(=O)=O|InChiKey: PSMMNJNZVZZNOI-SJILXJHISA-N|InChi: InChI=1S/C24H30ClN7O4S.C7H8O3S.H2O/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10;/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10);1H2/t13-,15-,17+;;/m0../s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥360 days if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|
